» Articles » PMID: 33672684

MicroRNAs: Their Role in Metastasis, Angiogenesis, and the Potential for Biomarker Utility in Bladder Carcinomas

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Mar 6
PMID 33672684
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Angiogenesis is the process of generating new capillaries from pre-existing blood vessels with a vital role in tumor growth and metastasis. MicroRNAs (miRNAs) are noncoding RNAs that exert post-transcriptional control of protein regulation. They participate in the development and progression of several cancers including bladder cancer (BLCA). In cancer tissue, changes in microRNA expression exhibit tissue specificity with high levels of stability and detectability. miRNAs are less vulnerable to degradation, making them novel targets for therapeutic approaches. A suitable means of targeting aberrant activated signal transduction pathways in carcinogenesis of BLCA is possibly through altering the expression of key miRNAs that regulate them, exerting a strong effect on signal transduction. Precaution must be taken, as the complexity of miRNA regulation might result in targeting several downstream tumor suppressors or oncogenes, enhancing the effect further. Since exosomes contain both mRNA and miRNA, they could therefore possibly be more effective in targeting a recipient cell if they deliver a specific miRNA to modify the recipient cell protein production and gene expression. In this review, we discuss the molecules that have been shown to play a significant role in BLCA tumor development. We also discuss the roles of various miRNAs in BLCA angiogenesis and metastasis. Advances in the management of metastatic BLCA have been limited; miRNA mimics and molecules targeted at miRNAs (anti-miRs) as well as exosomes could serve as therapeutic modalities or as diagnostic biomarkers.

Citing Articles

Progress in Precision Medicine for Head and Neck Cancer.

Vakili S, Behrooz A, Whichelo R, Fernandes A, Emwas A, Jaremko M Cancers (Basel). 2024; 16(21).

PMID: 39518152 PMC: 11544984. DOI: 10.3390/cancers16213716.


The Antimicrobial Peptide Merecidin Inhibit the Metastasis of Triple-Negative Breast Cancer by Obstructing EMT via miR-30d-5p/Vimentin.

Ma F, Song J, He M, Wang X Technol Cancer Res Treat. 2024; 23:15330338241281310.

PMID: 39267432 PMC: 11402084. DOI: 10.1177/15330338241281310.


Integrative analysis in head and neck cancer reveals distinct role of miRNome and methylome as tumour epigenetic drivers.

Mandic K, Milutin Gasperov N, Bozinovic K, Dediol E, Krasic J, Sincic N Sci Rep. 2024; 14(1):9062.

PMID: 38643268 PMC: 11032388. DOI: 10.1038/s41598-024-59312-z.


Do Histology and Primary Tumor Location Influence Metastatic Patterns in Bladder Cancer?.

Park H Curr Oncol. 2023; 30(10):9078-9089.

PMID: 37887556 PMC: 10605465. DOI: 10.3390/curroncol30100656.


An Overview of Angiogenesis in Bladder Cancer.

Elayat G, Punev I, Selim A Curr Oncol Rep. 2023; 25(7):709-728.

PMID: 37052868 PMC: 10256644. DOI: 10.1007/s11912-023-01421-5.


References
1.
Wu C, Lin W, Chang Y, Chen W, Chen M . Impact of CD44 expression on radiation response for bladder cancer. J Cancer. 2017; 8(7):1137-1144. PMC: 5463427. DOI: 10.7150/jca.18297. View

2.
Liu W, Qi L, Lv H, Zu X, Chen M, Wang J . MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy. BMC Cancer. 2015; 15:92. PMC: 4350852. DOI: 10.1186/s12885-015-1110-7. View

3.
Chaffer C, San Juan B, Lim E, Weinberg R . EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016; 35(4):645-654. DOI: 10.1007/s10555-016-9648-7. View

4.
Mylona E, Magkou C, Gorantonakis G, Giannopoulou I, Nomikos A, Zarogiannos A . Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. Anticancer Res. 2006; 26(5A):3567-71. View

5.
Zhang S, Zhang C, Liu W, Zheng W, Zhang Y, Wang S . MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3. Int J Oncol. 2015; 47(4):1351-60. DOI: 10.3892/ijo.2015.3117. View